AI-assisted engineering is useful when the experimental search space is much larger than the number of variants that can be built and tested, and when the desired performance can be measured with enough consistency to guide the next decision. Typical starting points include a polymerase that loses inhibitor tolerance when thermostability is improved, a reverse transcriptase that performs well on purified RNA but not in a one-step reagent, an oxidase with unwanted cross-reactivity, a CRISPR-associated enzyme with high background at the intended temperature, or a candidate that functions but cannot be expressed or purified reproducibly.
Sequence models, structural hypotheses, generative methods, fitness predictors, and active-learning algorithms can narrow or restructure the candidate set. They help select informative variants, balance diversity and predicted performance, and determine which uncertainty should be tested next.
Expression, biochemical function, application-assay behavior, specificity, robustness, stability, and manufacturability must be measured. A predicted fold, interaction pose, likelihood score, or fitness rank does not establish that an enzyme works in the intended diagnostic reagent.
The service may begin with an established parent enzyme, a family of homologs, a sequence and no experimental structure, a partially characterized mutation library, historical screening data, or a diagnostic performance specification without a selected enzyme. The appropriate route is determined by what information exists, what can be measured, and how far the proposed sequences move beyond the evidence domain. If the problem is primarily a wet formulation issue rather than an intrinsic enzyme property, our Lyophilized and Ambient-Stable Diagnostic Reagent Development platform may be a better first step. If the need is conventional engineering without an AI-led campaign, see Enzyme Engineering and Modification.
An AI enzyme program does not require the same starting data in every case. A cold-start project can use sequence families, evolutionary conservation, predicted or experimental structures, known catalytic motifs, and general pretrained representations to design a diverse first panel. A warm-start project adds project-specific activity, stability, expression, or assay data. A closed-loop project repeatedly updates design decisions using new experimental results, including failed variants. We do not apply a universal minimum data count because effective sample size depends on label quality, sequence diversity, assay noise, class balance, target distance, and the model.
Use homolog mining, motif and residue conservation, structure prediction, inverse-folding or language-model scores, physically informed filters, and diversity-aware library design. The first experiment is designed to learn the landscape as well as find hits.
Primary output: a defensible, diverse candidate panel and an information-rich screen.
Curate labels, identify batch and assay effects, define validation splits, combine pretrained representations with project data, estimate uncertainty, and rank variants within a stated applicability domain.
Primary output: prioritized candidates plus evidence about which predictions are reliable enough to test.
Use active learning or another iterative strategy to select candidates that trade off expected performance, uncertainty, diversity, and experimental cost. Capture every result with construct, plate, batch, and assay provenance for the next round.
Primary output: an evolving sequence-function model and experimentally confirmed leads.
(Creative Enzymes Diagnostic)
Research on data-efficient protein engineering has shown that pretrained protein representations can support useful design from small labeled data sets in specific systems. That result is encouraging, but it does not create a universal “low-N” guarantee. A dozen noisy endpoint labels from one plate may contain less usable information than a smaller set of replicated kinetic profiles; many nearly identical variants may provide less coverage than a deliberately diverse training set. We therefore assess information content, not only row count.
The portfolio is a set of connected entry points rather than a requirement to purchase every module. A project may enter through a specific property, an assay platform, a discovery question, a data problem, or a second-source requirement. It can expand only when the evidence shows that another workstream is limiting progress.
Define which sequence neighborhoods and structural hypotheses should be tested.
AI-Guided Diagnostic Enzyme Variant Design and Screening AI-Assisted Diagnostic Enzyme Mutation Library Design In Silico Structural Modeling and Enzyme-Substrate Interaction AnalysisImprove intrinsic or production-relevant properties while tracking trade-offs.
AI-Assisted Thermostability and Lyophilization Stability Engineering AI-Guided Activity and Kinetic Performance Optimization AI-Assisted Substrate Specificity and Cross-Reactivity Reduction AI-Guided Expression, Solubility and Manufacturability Optimization AI-Driven Multiparameter Enzyme Optimization for POCT ReagentsConnect enzyme changes to reaction-specific kinetics, background, matrix tolerance, and workflow constraints.
AI-Guided Polymerase and Reverse Transcriptase Engineering AI-Guided LAMP, RPA and Isothermal Enzyme Optimization AI-Assisted CRISPR/Cas Diagnostic Enzyme Engineering SupportSearch broader sequence space or engineer an independently evaluated source strategy.
AI-Driven De Novo Enzyme Discovery and Enzyme Mining AI-Assisted Second-Source and Sequence Equivalency EngineeringMake the experimental program learnable, auditable, and reusable across rounds.
Closed-Loop Design-Build-Test-Learn Enzyme Evolution AI-Ready Experimental Dataset Design and Screening Data Analysis
(Creative Enzymes Diagnostic)
For broader non-diagnostic use cases, Creative Enzymes also maintains an AI-Powered Enzyme Services portfolio. This page is narrower: candidates are selected and tested against diagnostic-reagent functions, such as target amplification, signal generation, background control, matrix tolerance, reagent stability, workflow timing, and raw-material manufacturability.
“AI” is not one method. A structure predictor, protein language model, inverse-folding model, mutation-effect predictor, supervised fitness model, docking workflow, and active-learning policy produce different outputs. We select a method stack according to the target, available evidence, candidate distance, assay capacity, licensing constraints, and decision. Tool and model versions are recorded because an output cannot be interpreted or reproduced without its configuration and inputs.
Identifies conserved residues, covariation, family boundaries, insertions, domain architecture, homolog diversity, and unusual sequence neighborhoods.
Useful output: allowed positions, risk positions, homolog panels, and evolutionary priors.Generates structural hypotheses where experimental models are absent or incomplete and highlights regions with different confidence or alternative states.
Useful output: candidate structural models, confidence maps, pocket and interface hypotheses.Proposes sequences compatible with a chosen backbone, motif, family constraint, or other conditioning information and expands beyond local single substitutions.
Useful output: diverse sequence candidates and designed libraries for further filtering.Uses pretrained representations, project labels, physicochemical descriptors, structural features, or ensembles to rank candidate variants and estimate uncertainty.
Useful output: predicted phenotype distributions, ranks, uncertainty, and applicability-domain flags.Examines hypotheses about enzyme-substrate, protein-nucleic-acid, cofactor, inhibitor, or interface geometry. Multiple states and controls may be needed.
Useful output: contact hypotheses, alternative poses, residue networks, and testable mutation ideas.Selects variants that balance predicted benefit, uncertainty, diversity, constraint satisfaction, and experimental information gain across rounds.
Useful output: the next experimental panel, not a claim that every selected sequence will succeed.
(Creative Enzymes Diagnostic)
| Computational output | What it can support | What it does not establish | Experimental follow-up |
|---|---|---|---|
| High sequence likelihood or evolutionary plausibility | A sequence resembles learned family constraints or occupies a plausible region of sequence space. | Correct catalytic activity, target specificity, reagent compatibility, expression, or stability. | Construct confirmation, expression screen, biochemical assay, and application assay. |
| Confident predicted fold | A candidate may adopt a modeled global structure under the model's assumptions. | Required conformational dynamics, catalytic geometry, oligomerization, cofactor state, or performance in the product matrix. | Protein-quality checks, functional assay, stability challenge, and structural/biophysical work when decision-relevant. |
| Predicted ligand, substrate, or nucleic-acid interaction | A testable hypothesis about binding mode, contacts, pocket shape, or interface residues. | Catalytic turnover, affinity under the assay condition, selectivity across interferents, or absence of off-target activity. | Kinetic or binding experiment, substrate/interferent panel, negative controls, and application-level confirmation. |
| Predicted stability change | A ranked hypothesis about a thermal or folding-related property within a defined model domain. | Storage stability, lyophilization recovery, freeze-thaw behavior, activity retention, or formulation compatibility. | Thermal/chemical characterization, activity after stress, formulation challenge, and storage study. |
| High supervised fitness score | Expected performance conditional on the training labels, features, validation design, and candidate domain. | Performance outside the sampled sequence or assay space, causal mechanism, or successful scale-up. | Blinded or held-out testing, replicate confirmation, orthogonal assays, representative matrix, and production evaluation. |
AlphaFold established highly accurate protein-structure prediction for many targets, ProteinMPNN demonstrated sequence design conditioned on a protein backbone, AlphaFold 3 expanded biomolecular interaction prediction, and RFdiffusion enabled new backbone and motif-scaffolding strategies. These are important advances, yet they solve different tasks. Enzyme catalysis may depend on protonation, cofactors, water, dynamics, transient conformations, oligomeric state, substrate orientation, and reaction conditions that are incompletely represented by a single static model. The structural modeling and interaction analysis service therefore returns confidence and limitations with the engineering hypotheses.
The model needs an objective, but a useful diagnostic target is rarely one number. A polymerase can become more thermostable while losing extension rate. A reporter enzyme can gain turnover but increase background with an endogenous substrate. A sample-preparation enzyme can digest an inhibitor more effectively while damaging the target analyte or impairing downstream amplification. A variant with excellent bench activity may express poorly, aggregate during purification, or fail after drying. We translate the product-use profile into measurable primary objectives, hard constraints, challenge conditions, and secondary attributes.
Extension and reverse-transcription kinetics, fidelity where relevant, hot-start behavior, inhibitor tolerance, target-length and structure effects, low-target amplification, signal, background, temperature window, and one-step compatibility.
Strand displacement, recombinase or accessory-enzyme compatibility, collateral or target cleavage, temperature tolerance, initiation time, background generation, specificity, and multiplex interactions.
Substrate and interferent panels, cofactor dependence, coupling efficiency, blank response, linearity-supporting kinetics, matrix behavior, pH window, and reagent stability.
Signal generation, substrate depletion, endogenous interference, partner-enzyme stoichiometry, rate limiting steps, optical compatibility, background, and response timing.
Short workflow time, small-volume surfaces, temperature excursions, dried-format recovery, expression, solubility, purification, lot comparability, device integration, and limited user steps.
Endpoint selection must reveal the failure the product team cares about. A high substrate concentration may conceal a higher apparent Km. A high target input may hide reduced low-target amplification. An activity measurement after ideal purification may not reveal host-derived interference or loss during a realistic process. We can connect variant engineering with Enzyme Activity and Stability Analysis, Molecular Diagnostic Enzyme and Master Mix Development, Enzyme Production and Engineering, and Enzyme QC and QA as the project matures.
| Target dimension | Representative question | Measurement design | Common hidden confounder |
|---|---|---|---|
| Activity and kinetics | Does the variant improve the rate or useful conversion in the intended operating window? | Substrate range, initial-rate or progress-curve logic, enzyme normalization, temperature and buffer controls | Different soluble expression or active-enzyme concentration masquerading as catalytic improvement |
| Specificity and background | Does intended signal improve without unacceptable off-target conversion or nonspecific amplification? | Substrate/interferent panel, negative and near-neighbor controls, blank and time-dependent background | Selection on a single desired substrate without counter-screen labels |
| Stability and formulation | Does activity persist after heat, hold, freeze-thaw, drying, or storage conditions relevant to the format? | Paired pre/post-stress function, formulation and process controls, reconstitution and matrix challenge | Thermal unfolding metric treated as a substitute for functional storage stability |
| Matrix and inhibitor tolerance | Does performance remain acceptable in representative sample components or extraction carryover? | Defined interferent levels, dilution series, sample pools where appropriate, spike and process controls | Matrix-dependent target recovery or optical effect misread as enzyme inhibition |
| Expression and manufacturability | Can the selected enzyme be produced, recovered, purified, formulated, and measured consistently? | Host/construct comparison, soluble yield, activity per culture and per protein, purification and hold observations | A small-scale tag or host effect that does not transfer to the intended construct and process |
One-shot generation can provide a useful first panel, but difficult diagnostic objectives usually benefit from feedback. A closed loop begins with explicit hypotheses and a candidate-selection policy. Sequences are built and verified, expressed under tracked conditions, and tested with controls that separate expression from intrinsic function and application behavior. Results are normalized without erasing meaningful batch or plate information. The model is then evaluated on held-out or future data, updated if appropriate, and used to select the next diverse panel.
(Creative Enzymes Diagnostic)
Negative results are not discarded. A variant that fails to express, loses activity only in matrix, changes specificity, or produces a non-monotonic signal can define the boundary of the usable sequence space. Failure codes are more informative than a blank cell: not built, no sequence confirmation, no expression, insoluble, below detection, assay interference, or true low function are different labels. The dedicated AI-Ready Experimental Dataset Design and Screening Data Analysis module helps establish those distinctions before a large campaign.
A paper integrating cell-free expression, functional assays, and machine learning illustrates how a DBTL workflow can map sequence-function relationships and use experimental feedback to design further variants. Its enzyme, assay throughput, and performance gains are system-specific. The transferable principle is that useful predictions depend on experimentally aligned labels and an iterative mechanism for testing them.
Diagnostic enzymes are multi-objective products. Collapsing all properties into one score can hide why a candidate ranks highly and can make the result sensitive to arbitrary weights. We instead define hard constraints, desirable directions, measurement uncertainty, and acceptable trade-offs. Candidate panels may include an expected high performer, a diverse high-uncertainty design, a conservative control, and variants that isolate a mechanistic hypothesis. The aim is to find a Pareto-useful set in which no candidate can be improved on one relevant property without losing another, then choose using product priorities and evidence.
No color or score alone determines advancement. The selection report records why each candidate is included and which hypothesis it tests.
A highly active but poorly soluble design may be retained as a mechanistic lead but not selected as the production lead. A slightly lower-activity variant may be preferred if it maintains function after drying and performs across representative inhibitors. A high-uncertainty variant may be valuable when it expands the model's knowledge, provided the experimental cost and risk are acceptable.
For POCT projects, the AI-Driven Multiparameter Enzyme Optimization for POCT Reagents route explicitly includes device temperature, small-volume surfaces, dried format, time-to-result, and manufacturing constraints.
(Creative Enzymes Diagnostic)
A machine-learning result can look convincing for the wrong reason. Closely related mutations may appear in both training and validation sets. Measurements from the same plate or expression batch can leak shared noise. A model may learn expression level instead of intrinsic catalytic performance. Replicate wells can inflate the apparent sample count. Missing values may be treated as low activity even when the construct was never built. A random split can overstate performance when the intended next candidates are farther from the training sequence space.
Choose random, grouped, position-held-out, parent-held-out, round-forward, or time-forward evaluation according to the intended prediction. Report similarity between training and proposed candidates.
Track plate, day, operator, reagent lot, expression batch, purification batch, instrument, control position, and normalization. Balance designs so biological effects are not inseparable from plate layout.
Preserve raw signal, processed phenotype, censoring, replicate rule, error flag, and exclusion reason. Do not silently convert missing, failed, saturated, or below-quantification results into one number.
Use ensemble disagreement, distance, calibrated intervals, conformal or other appropriate methods as scoped. Treat uncertainty as a decision aid, not an assurance that every unknown is captured.
Evaluate the model on variants generated after training. Confirm selected leads with independent expression, representative matrices, counter-screens, and orthogonal methods where they answer the decision.
Record input sequences, database versions, model/tool names and versions, parameters, filters, random seeds where relevant, construct identity, assay protocol, processing code, and decision date.
Model performance is reported with metrics that match the decision. Correlation may be insufficient when only the top-ranked variants will be built. Classification accuracy can be misleading with few true hits. Retrospective cross-validation does not equal prospective hit rate. We may examine rank correlation, top-k enrichment, calibration, precision/recall, error by sequence distance, and property-specific residuals, but no metric is interpreted outside the label and split design that produced it.
Data rights are agreed before work begins. Client-supplied sequences, structures, formulations, assay protocols, and screening data are handled according to the project agreement. Whether data may be used to train a project model, whether public databases or third-party tools are permitted, how outputs are retained, and which model licenses affect downstream use should be explicit. We do not assume permission to use confidential client data for unrelated model training.
(Creative Enzymes Diagnostic)
The service can be configured around the client's existing capabilities. A computational-only engagement may rank client-designed variants or create a proposed library for the client's laboratory, but the report will clearly separate predictions from confirmed function. An integrated engagement adds construct generation, expression, screening, confirmation, and iterative design. A data-partnership engagement focuses on making an existing screening program learnable and using its prospective results to improve candidate selection.
For teams with established build and test capacity. We review the target profile and data, select methods, generate or prioritize variants, document uncertainty and diversity, and return a construct-ready design package and recommended experimental plan.
For teams that want connected computational and wet-lab work. The project can include design, mutagenesis or synthesis, expression, screening, confirmation, model update, and lead handoff under stage-gated decisions.
For teams with recurring screening data. We establish schemas, QC rules, validation logic, model evaluation, candidate-selection policies, and reproducible transfer files so each round improves the next decision.
Useful inputs include the parent enzyme sequence and provenance, domain and construct boundaries, known homologs, experimental or predicted structures, substrates and cofactors, current buffer and formulation, intended diagnostic application, assay protocol, raw and processed historical data, plate maps, control definitions, known beneficial and failed variants, expression host and construct, manufacturing constraints, intellectual-property boundaries, required and excluded sequence changes, available material and throughput, target timeline, and the decision that the first round must enable. Unknown items can become explicit work packages rather than hidden assumptions.
A lead is transferred with its evidence boundary. The package states which sequence and construct were tested, how the enzyme was expressed and purified, which assay and conditions generated the result, which properties remain untested, and what changes require bridging. For further development, candidates may move into Comprehensive Enzymes Development and Validation, production and engineering, formulation development, or project-specific QC method work. The broader Molecular Diagnostic Enzymes and Kits portfolio can also provide reference starting materials where appropriate.
It can generate or rank hypotheses from sequence alone, especially when pretrained representations and homolog information are available. Sequence-only output does not prove expression, folding, catalysis, specificity, stability, matrix tolerance, or application performance. A cold-start project therefore uses diversity-aware candidates and an experiment designed to learn the landscape, followed by laboratory verification.
No. Experimental structures can be valuable, but predicted structures, homolog models, sequence-family evidence, known motifs, and project data may support a first design. Structural confidence varies by region and state. If catalytic function depends on a flexible loop, oligomer, cofactor, nucleic acid, or substrate pose, those limitations are included in the hypothesis and experimental plan.
There is no universal row count. Requirements depend on assay noise, replicate structure, sequence diversity, property complexity, hit frequency, candidate distance, missing data, and the intended model. A project can start without local labels using cold-start methods, while a supervised campaign needs enough informative, traceable data for its validation objective. We assess effective information rather than quoting a generic minimum.
Potentially. We first examine protocol changes, reagent and instrument versions, plate controls, batch structure, construct definitions, normalization, missingness, and whether raw data are available. Some data may be bridgeable with shared controls or covariates; other results may need to be analyzed as separate domains. Combining incompatible labels without documenting the difference can make a model appear accurate while reducing prospective usefulness.
Deliverables are defined in the agreement and may include tool/model identity and version, inputs, configuration, candidate scores, uncertainty, diversity measures, filters, and analysis files. Some third-party or proprietary tools can have licensing or disclosure constraints. We identify those constraints before use and ensure the decision package remains interpretable. Scores are reported with their applicability and validation boundaries.
Candidate selection can explicitly balance predicted performance with sequence, structural, or embedding-space diversity and uncertainty. We may cluster candidates, limit near-neighbor redundancy, include mechanistic controls, and reserve positions for information gain. The correct diversity depends on the assay budget and objective; maximizing novelty alone is not useful if candidates leave the supported functional domain.
Yes, when the properties can be measured or represented with clear constraints. We avoid hiding them in an unexplained composite score. Activity, specificity, stability, expression, inhibitor tolerance, formulation recovery, and manufacturability may be modeled separately and combined through hard constraints, Pareto analysis, or an agreed utility function. Experimental confirmation determines whether the trade-off is real.
No. A score is conditional on the training data, features, model, validation split, candidate domain, and label definition. Distribution shift, epistasis, assay noise, expression differences, missing cofactors, and unmodeled constraints can cause failure. We use scores to choose experiments and confirm performance with biochemical and application-relevant assays.
Ownership, permitted use, confidentiality, model-training rights, third-party tool licenses, retention, and transfer format are project-agreement matters. We do not assume that confidential client data may be reused for unrelated training. The data-governance section of the project defines what is supplied, generated, retained, returned, and permitted for future rounds.
Not on the basis of design and development data alone. These services support RUO and industrial diagnostic-reagent development. The sponsor or legal manufacturer must establish intended use, design controls, analytical and clinical performance, production controls, stability, specifications, labeling, registration, and market authorization. An AI-assisted design method does not change those responsibilities.
Share the parent enzyme or target function, current assay, available sequence/structure/screening data, performance gap, experimental throughput, product constraints, and data-governance requirements. Creative Enzymes can propose a cold-start, warm-start, or closed-loop program that connects computational hypotheses to sequence-defined constructs, application-relevant testing, and a traceable transfer package.
RUO and industrial diagnostic-reagent development only. Predictions and engineered candidates do not constitute direct diagnostic use, clinical validation, therapeutic use, food use, regulatory approval, or market authorization.
Contact Creative Enzymes